Process for preparing injectable technetium-99m or indium-113m preparation of high specific activity by contacting an aqueous solution of such radionuclide of low specific activity with a metal hydroxide precipitate, separating the precipitate with the radionuclide concentrated therein and dissolving the precipitate in an aqueous solution of a chelating agent.
Treatment of rheumatoid arthritis by administering a radioactive compound to the inflamed synovium of the articular joint. The compound comprises an aggregate suspension having a radionuclide entrapped therein. The aggregate suspension is a ferric or aluminum hydroxide aggregate, and the radionuclide is selected from the group consisting of .sup.166 Holmium, .sup.153 Samarium, .sup.175 Ytterbium, .sup.169 Erbium, and .sup.176m Lutetium. The radionculide may also consist of .sup.51 Chromium. Suitable leakage inhibitors or agents to reduce leakage of the radionuclide from the articular joint is included as part of the chemical composition of the final drug form.
A radioactive diagnostic agent which comprises deferoxamine, and a physiologically active compound and a radioactive metallic element chemically connected thereto with or without intervention of any other chemical bonding, which is characteristic in having a high stability even after being administered into a human body and showing substantially the same behavior in a human body as said physiologically active compound itself.
A novel chemical method of labeling porphyrin compounds, specifically hematoporphyrin derivative (HPD), with the radionuclide .sup.111 In or .sup.113m In producing a radioactive tracer material suitable for biomedical applications. HPD labeled with .sup.111 In or .sup.113m In is biologically active in vivo and is preferentially taken up by tumors. This provides a simple and specific means of localizing and detecting neoplasms in man or in animal by scintigraphic imaging techniques.
.sup.1/3 Holmium in a carrier metallic hydroxide aggregate is disclosed for the treatment of arthritis and, in particular, rheumatoid arthritis. The compound disclosed preferably has a particle size of 1 to 40 microns, Beta energy emissions in the range of 1.76-1.84 MeV, low levels of gamma ray emissions and a radioactive half-life of 26.8 hours. The preferred metallic hydroxide is selected from the group consisting of Ferric Hydroxide, Aluminum Hydroxide, Bismuth Hydroxide, Chromium Hydroxide, Cupric Hydroxide, Manganese Hydroxide and Stannous Hydroxide. Methods are also disclosed for the preparation of the compound, as well as for the methods of its administration to a patient in need thereof.
A radiopharmaceutical chemical compound comprising a radioactive isotope, other than an isotope of iodine, in chemical combination with at least one amine group. The compound has a lipophilicity sufficiently high at a pH of 7.6 to permit passage of the compound from the blood of a mammal into a target organ or tissue and sufficiently low at a pH of 6.6 to prevent rapid return of the compound from the target organ or tissue to the blood. The compound has a percent protein binding of less than ninety percent. A method for selectively depositing a radiopharmaceutical compound in at least one target tissue or organ of a mammal, which tissue or organ has a significantly different intracellular pH than the blood of the mammal, by introducing the compound of the invention into the bloodstream of the mammal.
